Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact

Citations to this article

ROCK2 inhibitor belumosudil overcomes resistance to KRAS inhibition in pancreatic cancer models
Alejandra M. Marinelarena, Thao D. Pham, Jeffrey H. Becker, Apurba Majumder, Hidayatullah G. Munshi
Alejandra M. Marinelarena, Thao D. Pham, Jeffrey H. Becker, Apurba Majumder, Hidayatullah G. Munshi
View: Text | PDF
Research Letter In-Press Preview Cell biology Oncology

ROCK2 inhibitor belumosudil overcomes resistance to KRAS inhibition in pancreatic cancer models

  • Text
  • PDF
Abstract

Authors

Alejandra M. Marinelarena, Thao D. Pham, Jeffrey H. Becker, Apurba Majumder, Hidayatullah G. Munshi

×

Loading citation information...
Advertisement

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts